However, unlike EGFR-mutant non-Sq NSCLC that derive impressive clinical benefit from EGFR inhibitors, thus far, KRAS G12C inhibitors have shown relatively less pronounced clinical activity in KRAS G12C-mutant non-Sq NSCLC57–59. Here, KRAS is linked to non-small cell lung carcinoma.